Total patients (N = 151) | DPP4i-treated patients (N = 108) | Non DPP4i-treated patients (N = 43) | p value | |
---|---|---|---|---|
Age (years) | 61.1 ± 12.2 | 60.7 ± 11.5 | 62.3 ± 14.1 | 0.473 |
Gender (% female) | 79 (52.32%) | 53 (48.18%) | 26 (63.41%) | 0.096 |
Duration of DM (years) | 16.7 ± 9 | 16.3 ± 9 | 18 ± 9.1 | 0.297 |
Pre-treatment HbA1c (%NGSP) | 8.8 ± 1.5 | 8.9 ± 1.4 | 8.4 ± 1.6 | 0.093 |
Baseline BW (kg) | 78.2 ± 17.8 | 77.6 ± 18.7 | 79.8 ± 15.3 | 0.504 |
Baseline BMI (kg/m2) | 29.8 ± 6 | 29.4 ± 6.1 | 31 ± 5.5 | 0.142 |
BMI categories (%) | ||||
< 23.0 kg/m2 | 12 (7.95%) | 10 (9.09%) | 2 (4.88%) | 0.395 |
≥ 23.0– < 25.0 kg/m2 | 17 (11.26%) | 15 (13.64%) | 2 (4.88%) | 0.130 |
≥ 25.0– < 30.0 kg/m2 | 56 (37.09%) | 42 (38.18%) | 14 (34.15%) | 0.648 |
≥ 30.0 kg/m2 | 66 (43.71%) | 43 (39.09%) | 23 (56.1%) | 0.061 |
Diabetes treatment (%) | ||||
No oral therapy | 3 (1.99%) | (0%) | 3 (7.32%) | 0.004 |
1 oral therapy | 10 (6.62%) | 3 (2.73%) | 7 (17.07%) | 0.002 |
2 oral therapy | 30 (19.87%) | 14 (12.73%) | 16 (39.02%) | < 0.001 |
≥ 3 oral therapy | 108 (71.52%) | 93 (84.55%) | 15 (36.59%) | < 0.001 |
Concomitant SU (%) | 84 (55.63%) | 64 (58.18%) | 20 (48.78%) | 0.301 |
Concomitant TZD (%) | 74 (49.01%) | 53 (48.18%) | 21 (51.22%) | 0.740 |
Insulin treatment | 50 (33.11%) | 33 (30%) | 17 (41.46%) | 0.183 |
Comorbid conditions (%) | ||||
Ischemic heart disease | 11 (7.28%) | 8 (7.27%) | 3 (7.32%) | 0.765 |
Congestive heart failure | 3 (1.99%) | 1 (0.91%) | 2 (4.88%) | 0.026 |
Cerebrovascular disease | 2 (1.32%) | 2 (1.82%) | 0 (0%) | 0.565 |
Duration of SGLT2i (months) | 17.8 ± 6.9 | 18.2 ± 6.7 | 16.9 ± 7.3 | 0.543 |